Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin
- PMID: 3169375
- DOI: 10.1177/030006058801600410
Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin
Abstract
In twelve patients affected by small bowel bacterial overgrowth, diagnosed by means of the lactulose hydrogen breath test, the therapeutic efficacy of a non-absorbable derivative of rifamycin, rifaximin, was evaluated. This study showed that this drug has a satisfactory therapeutic efficacy in contaminated small bowel syndrome and, at the doses tested, is free of side-effects.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
